Puma Non Current Liabilities Total from 2010 to 2026
| PBYI Stock | USD 6.48 0.05 0.78% |
Non Current Liabilities Total | First Reported 2011-09-30 | Previous Quarter 11.1 M | Current Value 4.9 M | Quarterly Volatility 59.3 M |
Check Puma Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Puma Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 15 M, Other Operating Expenses of 179.8 M or Operating Income of 37.4 M, as well as many indicators such as Price To Sales Ratio of 0.61, Dividend Yield of 0.0 or PTB Ratio of 1.76. Puma financial statements analysis is a perfect complement when working with Puma Biotechnology Valuation or Volatility modules.
Puma | Non Current Liabilities Total | Build AI portfolio with Puma Stock |
The Non Current Liabilities Total trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Puma Biotechnology's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Puma Biotechnology over the last few years. It is Puma Biotechnology's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Puma Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 52,167,580 | |
| Geometric Mean | 12,898,237 | |
| Coefficient Of Variation | 111.04 | |
| Mean Deviation | 50,476,228 | |
| Median | 27,418,472 | |
| Standard Deviation | 57,926,357 | |
| Sample Variance | 3355.5T | |
| Range | 157.3M | |
| R-Value | 0.45 | |
| Mean Square Error | 2847.4T | |
| R-Squared | 0.20 | |
| Significance | 0.07 | |
| Slope | 5,186,930 | |
| Total Sum of Squares | 53687.4T |
Puma Non Current Liabilities Total History
About Puma Biotechnology Financial Statements
Investors use fundamental indicators, such as Puma Biotechnology's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Puma Biotechnology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 28.9 M | 27.4 M |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out the analysis of Puma Biotechnology Correlation against competitors. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.